Wellington Shields Capital Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.19M Sell
4,721
-3,600
-43% -$775K 0.15% 110
2026
Q1
$1.81M Sell
8,321
-7,047
-46% -$1.56M 0.27% 78
2025
Q4
$3.51M Hold
15,368
0.51% 43
2025
Q3
$3.56M Sell
15,368
-20
-0.1% -$4.07K 0.54% 43
2025
Q2
$2.86M Sell
15,388
-100
-0.6% -$18.6K 0.48% 47
2025
Q1
$3.25M Sell
15,488
-5,520
-26% -$1.07M 0.59% 44
2024
Q4
$3.73M Sell
21,008
-24
-0.1% -$4.41K 0.66% 34
2024
Q3
$4.15M Hold
21,032
0.72% 27
2024
Q2
$3.61M Buy
21,032
+680
+3% +$113K 0.66% 33
2024
Q1
$3.71M Sell
20,352
-700
-3% -$121K 0.7% 31
2023
Q4
$3.26M Buy
21,052
+383
+2% +$55.8K 0.41% 31
2023
Q3
$3.08M Sell
20,669
-86
-0.4% -$12.6K 0.41% 29
2023
Q2
$2.8M Sell
20,755
-1,957
-9% -$287K 0.34% 36
2023
Q1
$3.62M Buy
22,712
+501
+2% +$76.6K 0.44% 28
2022
Q4
$3.59M Buy
22,211
+1
+0% +$153 0.44% 24
2022
Q3
$2.98M Sell
22,210
-2,549
-10% -$366K 0.71% 29
2022
Q2
$3.79M Sell
24,759
-48,096
-66% -$7.35M 0.47% 26
2022
Q1
$4.07M Buy
72,855
+39,864
+121% +$5.79M 0.45% 31
2021
Q4
$4.47M Buy
32,991
+5,501
+20% +$650K 0.57% 33
2021
Q3
$2.96M Sell
27,490
-5,853
-18% -$669K 0.4% 44
2021
Q2
$3.76M Sell
33,343
-64,077
-66% -$7.22M 0.45% 43
2021
Q1
$10.5M Buy
97,420
+63,633
+188% +$6.81M 1% 19
2020
Q4
$3.62M Buy
33,787
+6,336
+23% +$609K 0.48% 46
2020
Q3
$2.4M Sell
27,451
-198
-0.7% -$18.6K 0.38% 53
2020
Q2
$2.71M Buy
27,649
+3,042
+12% +$268K 0.44% 51
2020
Q1
$1.88M Buy
24,607
+172
+0.7% +$14.7K 0.35% 61
2019
Q4
$2.16M Hold
24,435
0.33% 71
2019
Q3
$1.85M Buy
24,435
+2,986
+14% +$205K 0.3% 77
2019
Q2
$1.56M Sell
21,449
-5,838
-21% -$459K 0.26% 85
2019
Q1
$2.2M Sell
27,287
-750
-3% -$61.4K 0.37% 55
2018
Q4
$2.58M Sell
28,037
-300
-1% -$26.4K 0.49% 41
2018
Q3
$2.68M Sell
28,337
-2,675
-9% -$254K 0.43% 48
2018
Q2
$2.87M Sell
31,012
-14,368
-32% -$1.4M 0.48% 42
2018
Q1
$4.29M Buy
45,380
+3,425
+8% +$376K 0.65% 27
2017
Q4
$4.06M Sell
41,955
-7,061
-14% -$665K 0.63% 30
2017
Q3
$4.36M Buy
49,016
+770
+2% +$58.6K 0.72% 27
2017
Q2
$3.5M Sell
48,246
-8,678
-15% -$583K 0.57% 36
2017
Q1
$3.71M Sell
56,924
-6,228
-10% -$392K 0.6% 35
2016
Q4
$3.96M Sell
63,152
-782
-1% -$47.7K 0.66% 30
2016
Q3
$4.03M Buy
63,934
+7,700
+14% +$498K 0.7% 30
2016
Q2
$3.48M Sell
56,234
-2,873
-5% -$175K 0.59% 36
2016
Q1
$3.38M Sell
59,107
-1,508
-2% -$84.1K 0.59% 37
2015
Q4
$3.59M Sell
60,615
-9,945
-14% -$573K 0.61% 33
2015
Q3
$3.84M Sell
70,560
-9,097
-11% -$592K 0.66% 28
2015
Q2
$5.35M Buy
79,657
+16,975
+27% +$1.11M 0.82% 20
2015
Q1
$3.67M Buy
62,682
+23,080
+58% +$1.39M 0.55% 38
2014
Q4
$2.59M Sell
39,602
-1,100
-3% -$69.3K 0.41% 51
2014
Q3
$2.35M Sell
40,702
-1,200
-3% -$66.6K 0.39% 49
2014
Q2
$2.37M Hold
41,902
0.37% 49
2014
Q1
$2.15M Hold
41,902
0.37% 48
2013
Q4
$2.21M Hold
41,902
0.4% 48
2013
Q3
$1.87M Hold
41,902
0.36% 52
2013
Q2
$1.73M Buy
+41,902
New +$1.83M 0.31% 60

Other funds holding ABBV

Wellington Shields Capital Management's ABBV Position: Q2 2026 in Review

Wellington Shields Capital Management reduced its AbbVie (ABBV) stake by 43% in Q2 2026, selling an estimated $775K and leaving 4,721 shares worth $1.19M. The position accounts for 0.15% of the portfolio, ranked #110.

Wellington Shields Capital Management first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. The position peaked at $10.5M in Q1 2021. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Wellington Shields Capital Management held 4,721 shares of AbbVie worth $1.19M as of Q2 2026.
  • Wellington Shields Capital Management sold 3,600 AbbVie shares in Q2 2026, an estimated $775K.
  • AbbVie made up 0.15% of Wellington Shields Capital Management's portfolio in Q2 2026, its #110 holding.
  • Wellington Shields Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • Wellington Shields Capital Management's AbbVie position peaked at $10.5M in Q1 2021.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Wellington Shields Capital Management's 13F filing for Q2 2026, filed 10 Aug 2026.